Evidence map›Paper›PMID 37164043›Full record

ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2023

Emulating Target Trials With Real-World Data to Inform Health Technology Assessment: Findings and Lessons From an Application to Emergency Surgery.

Silvia Moler-Zapata, Andrew Hutchings, Stephen O'Neill, Richard J Silverwood, Richard Grieve

Open access · hybridAbstract readControlled Clinical Trial
PubMed Publisher
In one paragraph

Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Distributional Cost-Effectiveness Analysis Using Microsimulation in R: A Tutorial.Medical decision making : an international journal of the Society for Medical Decision Making · 2026
    Article
  3. Evaluation of clinical utility in emulated clinical trials.European journal of epidemiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Actions for stakeholders to develop better real-world evidence for HTA bodies/payers decision making.International journal of technology assessment in health care · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Silvia Moler-ZapataDepartment of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, England, UK. Electronic address: silvia.moler@lshtm.ac.uk.
Andrew HutchingsDepartment of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, England, UK.
Stephen O'NeillDepartment of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, England, UK.
Richard J SilverwoodCentre for Longitudinal Studies, UCL Social Research Institute, University College London, London, England, UK.
Richard GrieveDepartment of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, England, UK.
London School of Hygiene & Tropical Medicine · GBUniversity College London · GB

Funding

Department of Health 18/02/25
6 · The paper itself

Abstract

objectivesInternational health technology assessment (HTA) agencies recommend that real-world data (RWD) are used in some circumstances to add to the evidence base about the effectiveness and cost-effectiveness of health interventions. The target trial framework applies the design principles of randomized-controlled trials to RWD and can help alleviate inevitable concerns about bias and design flaws with nonrandomized studies. This article aimed to tackle the lack of guidance and exemplar applications on how this methodology can be applied to RWD to inform HTA decision making.

methodsWe use Hospital Episode Statistics data from England on emergency hospital admissions from 2010 to 2019 to evaluate the cost-effectiveness of emergency surgery for 2 acute gastrointestinal conditions. We draw on the case study to describe the main challenges in applying the target trial framework alongside RWD and provide recommendations for how these can be addressed in practice.

resultsThe 4 main challenges when applying the target trial framework to RWD are (1) defining the study population, (2) defining the treatment strategies, (3) establishing time zero (baseline), and (4) adjusting for unmeasured confounding. The recommendations for how to address these challenges, mainly around the incorporation of expert judgment and use of appropriate methods for handling unmeasured confounding, are illustrated within the case study.

conclusionsThe recommendations outlined in this study could help future studies seeking to inform HTA decision processes. These recommendations can complement checklists for economic evaluations and design tools for estimating treatment effectiveness in nonrandomized studies.

Indexed as

Technology Assessment, BiomedicalCost-Benefit AnalysisEnglandHumanscomparative effectivenessemergency surgeryhealth technology assessmentreal-world datatarget trial framework

Identifiers

PMID37164043
OpenAlexW4376132155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.